|CCL 06.04.04 Structure Based Drug Discovery, Whistler, British Columbia|
From: chemistry-request at ccl.net
To: chemistry-request at ccl.net
Date: Sun Oct 23 21:21:24 2005
Subject: 06.04.04 Structure Based Drug Discovery, Whistler, British Columbia
Structure Based Drug Discovery (D6) Supported by Chiron Corporation Organizers: Stephen K. Burley, Brian K. Shoichet and Paul A. Bartlett April 4 - 9, 2006 Fairmont Chateau Whistler Whistler, British Columbia http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=771 Meeting Summary This conference will focus on several exciting new developments in Structure Based Drug Discovery, including: fragment based lead discovery/lead optimization, high-throughput X-ray and NMR structure determination of protein ligand complexes, computational analyses of ligand-receptor interactions and prediction of novel ligands, ligand binding selectivity, and ADME/toxicity properties. Major/pivotal problems facing both academic and industrial scientists include: (a) understanding precisely what constitutes a good starting point for lead optimization, (b) understanding how best to optimize selectivity and avoid problems with ADME/toxicity, (c) understanding the limitations of currently available in silico methods, (d) understanding how to combine the results of biophysical characterization of protein-ligand interactions with medicinal chemistry to produce potent/selective lead compounds, and (e) developing sufficient expertise/experience to bring membrane proteins and macromolecular interactions within the purview of structure based drug discovery. Upon completion of this conference, participants should: - Appreciate the challenges represented by membrane proteins and macromolecular interactions as targets for structure based drug discovery. - Understand current approaches to fragment based drug discovery. - Appreciate the state-of-the-art in automated approaches to determination of protein-ligand complex structures with solution NMR spectroscopy and X-ray crystallography. - Understand the roles that homology modeling and computational docking play in structure based drug discovery. - Appreciate the contributions that structural studies can make to lead optimization and our understanding of selectivity and ADME/Toxicity. - Understand the limitations of current in silico methods for de novo drug discovery.NOTE THAT E-MAIL ADDRESSES HAVE BEEN MODIFIED!!!
All @ signs were changed to %% to fight spam. Before you send e-mail, you need to change %% to @
For example: change joe%%big123comp.com to firstname.lastname@example.org
Please let colleagues know about conference listingts at Computational Chemistry List Conference Page at http://www.ccl.net/chemistry/a/conferences/.
Please help: If you find this conference list useful but you noticed some conference missing, please consider including it here by using the Conference Submission Page. It is free but your support is welcome. You will help others!!!
|Modified: Mon Oct 24 01:21:24 2005 GMT|
|Page accessed 6940 times since Mon Oct 24 01:21:24 2005 GMT|
Please help maintain CCL: If you found that your conference is listed here, please consider supporting CCL as a Supporting Member or use other Paid Services of CCL to ensure the continuation of this useful service. We cannot do it without your help.